Research programme: erymethionase therapeutics - ERYTECH Pharma

Drug Profile

Research programme: erymethionase therapeutics - ERYTECH Pharma

Alternative Names: Erymet; Erymethionase programme; ERYZYME

Latest Information Update: 06 Apr 2017

Price : $50

At a glance

  • Originator ERYtech Pharma
  • Developer ERYtech Pharma; Fox Chase Cancer Center
  • Class Enzymes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Homocystinuria; Solid tumours

Most Recent Events

  • 23 Mar 2017 ERYTECH Pharma and Fox Chase Cancer Center collaborate on erymethionase thrapeutics for Homocystinuria
  • 23 Mar 2017 Preclinical trials in Homocystinuria in France (Parenteral)
  • 10 Oct 2016 Preclinical trials in Solid tumours in France (Parenteral) before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top